Pharmacy expert consensus on small interfering RNA lipid-lowering drugs
Small interfering RNA(siRNA)lipid-lowering drugs are a new class of lipid-lowering agents.At present,there is little evidence-based evidence and practical experience for this class of drugs.In order to strengthen the awareness of medical work-ers and standardize the rational use of such drugs in clinical practice,led by the Beijing Hospital,the National Center for Geriat-rics,Geriatric Pharmacy Professional Committee of Chinese Medical Education Association and Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association organized relevant clinical medicine,pharmacy and evidence-based experts.Based on the evidence-based evidence and clinical practice,Delphi method was used to collect expert opinions,and fully discus-sion was performed through three rounds of expert consultation.The consensus introduced the mechanism of siRNA lipid-lowering drugs,and taking the marketed drug inclisiran as an example,the clinical evidence and drug safety were described,in order to provide reference for the standardized clinical application of siRNA lipid-lowering drugs.
small interfering RNAatherosclerotic cardiovascular diseaselow density lipoprotein cholesterininclisiranexpert consensus
NETL
NSTL
万方数据
维普
